Aim: Patients with polycythemia vera (PV), a rare and chronic blood cancer, are at a higher
risk for thromboembolic events, progression to myelofibrosis, and leukemic transformation.
In 2021, ropeginterferon alfa-2b-njft (BESREMi®) was approved in the US ...